Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.